Education
About Us
Working with TipRanks
Follow Us
Mochida Pharmaceutical Co., Ltd. (JP:4534)
:4534
4534 Stock Chart & Stats
¥3615.00
-¥40.00(-1.17%)
At close: 4:00 PM EST
¥3615.00
-¥40.00(-1.17%)
Day’s Range― - ―
52-Week Range¥2,836.00 - ¥3,965.00
Previous CloseN/A
Volume18.00K
Average Volume (3M)34.37K
Market Cap
¥125.57B
Enterprise Value¥100.14B
Total Cash (Recent Filing)¥54.69B
Total Debt (Recent Filing)¥830.00M
Price to Earnings (P/E)12.6
Beta0.62
Next Earnings
May 18, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield2.34%
Share Statistics
EPS (TTM)70.12
Shares Outstanding36,390,000
10 Day Avg. Volume38,620
30 Day Avg. Volume34,366
Financial Highlights & Ratios
PEG Ratio0.75
Price to Book (P/B)0.86
Price to Sales (P/S)1.07
P/FCF Ratio15.67
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / Strong Balance SheetMinimal leverage and a robust equity ratio provide durable financial flexibility: the company can fund R&D, absorb reimbursement pressure, pursue selective licensing or M&A, and maintain operations through industry cycles without risking solvency.
Sustainable Profit MarginsConsistently healthy gross and net margins suggest structural cost advantages and pricing power in niche therapeutic areas. This margin resilience supports reinvestment in development, stable earnings retention, and helps buffer against slower revenue periods long term.
Strong Cash Generation Versus EarningsA strong FCF-to-net-income ratio implies the business converts earnings into cash effectively, enabling dividends, debt avoidance, and reinvestment. Even with some volatility, reliable cash conversion is a durable foundation for funding pipelines and partner commercialization.
Bears Say
Declining Revenue Growth TrendA multi-year slowdown and a recent significant revenue drop are structural concerns: shrinking top-line momentum limits scale benefits, reduces funds for R&D and commercialization, and increases reliance on a narrower product set or partner in-licensing for growth.
Volatile Free Cash Flow GrowthVolatile FCF growth complicates long-term planning for drug development, marketing, and capital allocation. Unpredictable free cash flow increases execution risk for multi-year clinical programs or licensing deals and can pressure dividends or discretionary investments.
Slightly Declining Return On EquityA gradual decline in ROE signals weakening capital efficiency that may reflect product life-cycle headwinds or intensifying competition. If sustained, lower ROE reduces the company's ability to generate attractive shareholder returns from existing capital.
Mochida Pharmaceutical Co., Ltd. News
4534 FAQ
What was Mochida Pharmaceutical Co., Ltd.’s price range in the past 12 months?
Mochida Pharmaceutical Co., Ltd. lowest stock price was ¥2836.00 and its highest was ¥3965.00 in the past 12 months.
What is Mochida Pharmaceutical Co., Ltd.’s market cap?
Mochida Pharmaceutical Co., Ltd.’s market cap is ¥125.57B.
When is Mochida Pharmaceutical Co., Ltd.’s upcoming earnings report date?
Mochida Pharmaceutical Co., Ltd.’s upcoming earnings report date is May 18, 2026 which is in 70 days.
How were Mochida Pharmaceutical Co., Ltd.’s earnings last quarter?
Mochida Pharmaceutical Co., Ltd. released its earnings results on Feb 06, 2026. The company reported ¥70.12 earnings per share for the quarter, beating the consensus estimate of N/A by ¥70.12.
Is Mochida Pharmaceutical Co., Ltd. overvalued?
According to Wall Street analysts Mochida Pharmaceutical Co., Ltd.’s price is currently Overvalued.
Does Mochida Pharmaceutical Co., Ltd. pay dividends?
Mochida Pharmaceutical Co., Ltd. pays a Semiannually dividend of ¥40 which represents an annual dividend yield of 2.34%. See more information on Mochida Pharmaceutical Co., Ltd. dividends here
What is Mochida Pharmaceutical Co., Ltd.’s EPS estimate?
Mochida Pharmaceutical Co., Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Mochida Pharmaceutical Co., Ltd. have?
Mochida Pharmaceutical Co., Ltd. has 36,390,000 shares outstanding.
What happened to Mochida Pharmaceutical Co., Ltd.’s price movement after its last earnings report?
Mochida Pharmaceutical Co., Ltd. reported an EPS of ¥70.12 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -2.537%.
Which hedge fund is a major shareholder of Mochida Pharmaceutical Co., Ltd.?
Currently, no hedge funds are holding shares in JP:4534
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Mochida Pharmaceutical Co., Ltd.
Mochida Pharmaceutical Co., Ltd. produces and sells pharmaceuticals, skincare products, and diagnostics solutions in Japan. The company provides cardiovascular, analgesic, gastrointestinal, neurological, anti-infective, antidiabetics, and anticancer products, as well as hormone and biological preparations, and biosimilars; diagnostic reagents, such as reagents for fertility/infertility and other reagents; and face and body care, hair care, and skincare products, as well as dermatology, psychiatry, obstetrics, and gynecology products. It also developing drugs for the treatment of intractable diseases. The company has collaboration agreements with Amarin Corporation plc for the development and commercialization of ethyl icosapentate products; and Gene Techno Science Co., Ltd. to develop new regenerative medicine for the treatment of digestive rare and intractable diseases, such as congenital isolated hypoganglionosis. Mochida Pharmaceutical Co., Ltd. was founded in 1913 and is headquartered in Tokyo, Japan.
Technical Analysis
Kaken Pharmaceutical Co
―
Kissei Pharmaceutical Co
―
Towa Pharmaceutical Co
―
KYORIN Pharmaceutical Co.,Ltd.
―
SAWAI GROUP HOLDINGS Co., Ltd.
―
Options Prices
Currently, No data available
---